Chemours Net Worth

Chemours Net Worth Breakdown

  CC
The net worth of Chemours Co is the difference between its total assets and liabilities. Chemours' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Chemours' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Chemours' net worth can be used as a measure of its financial health and stability which can help investors to decide if Chemours is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Chemours Co stock.

Chemours Net Worth Analysis

Chemours' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Chemours' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Chemours' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Chemours' net worth analysis. One common approach is to calculate Chemours' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Chemours' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Chemours' net worth. This approach calculates the present value of Chemours' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Chemours' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Chemours' net worth. This involves comparing Chemours' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Chemours' net worth relative to its peers.

Enterprise Value

5.32 Billion

To determine if Chemours is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Chemours' net worth research are outlined below:
Chemours had very high historical volatility over the last 90 days
The company generated the yearly revenue of 6.03 B. Annual Net Loss to common stockholders was (238 M) with gross profit of 1.62 B.
Chemours has a strong financial position based on the latest SEC filings
Over 83.0% of the company shares are held by institutions such as insurance companies
Latest headline from zacks.com: Acquisition by Erin Kane of 8547 shares of Chemours subject to Rule 16b-3
Chemours uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Chemours Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Chemours' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Chemours' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Chemours is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemours Co backward and forwards among themselves. Chemours' institutional investor refers to the entity that pools money to purchase Chemours' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Lsv Asset Management2024-09-30
1.9 M
Norges Bank2024-06-30
1.7 M
Appian Way Asset Management2024-09-30
1.7 M
Luminus Management, Llc2024-09-30
1.6 M
Bank Of New York Mellon Corp2024-06-30
1.6 M
Massachusetts Financial Services Company2024-09-30
1.5 M
American Century Companies Inc2024-09-30
1.5 M
Dimensional Fund Advisors, Inc.2024-09-30
1.5 M
Vision One Management Partners Lp2024-09-30
1.4 M
Fmr Inc2024-09-30
18.1 M
Blackrock Inc2024-06-30
16.3 M
Note, although Chemours' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Chemours' market capitalization trends

The company currently falls under 'Mid-Cap' category with a market capitalization of 2.88 B.

Market Cap

3.63 Billion

Project Chemours' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.03)(0.03)
Return On Capital Employed(0.02)(0.02)
Return On Assets(0.03)(0.03)
Return On Equity(0.32)(0.31)
The company has Net Profit Margin (PM) of 0.01 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.1 %, which signifies that for every $100 of sales, it has a net operating income of $0.1.
When accessing Chemours' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Chemours' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Chemours' profitability and make more informed investment decisions.
Please note, the presentation of Chemours' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chemours' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Chemours' management manipulating its earnings.

Evaluate Chemours' management efficiency

Chemours has Return on Asset (ROA) of 0.0397 % which means that for every $100 of assets, it generated a profit of $0.0397. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1102 %, which means that it produced $0.1102 on every 100 dollars invested by current stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. The current year's Return On Capital Employed is expected to grow to -0.02. At present, Chemours' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 703.5 M, whereas Total Assets are forecasted to decline to about 7.5 B.
Last ReportedProjected for Next Year
Book Value Per Share 4.96  8.77 
Tangible Book Value Per Share 4.26  7.71 
Enterprise Value Over EBITDA 39.56  41.53 
Price Book Value Ratio 6.37  8.43 
Enterprise Value Multiple 39.56  41.53 
Price Fair Value 6.37  8.43 
Enterprise Value7.8 B5.3 B
Chemours showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue
1.1428
Revenue
5.7 B
Quarterly Revenue Growth
0.009
Revenue Per Share
38.519
Return On Equity
0.1102
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemours insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemours' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chemours insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chemours Corporate Filings

F4
19th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
13th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
F3
13th of August 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
Chemours time-series forecasting models is one of many Chemours' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chemours' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Chemours Earnings per Share Projection vs Actual

Chemours Corporate Directors

Curtis AnastasioIndependent DirectorProfile
Curtis CrawfordIndependent DirectorProfile
Mary CranstonIndependent DirectorProfile
Bradley BellIndependent DirectorProfile
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Diversified Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.65)
Dividend Share
1
Earnings Share
0.5
Revenue Per Share
38.519
Quarterly Revenue Growth
0.009
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.